Exercise benefits on Alzheimer's disease: State-of-the-science.


Journal

Ageing research reviews
ISSN: 1872-9649
Titre abrégé: Ageing Res Rev
Pays: England
ID NLM: 101128963

Informations de publication

Date de publication:
09 2020
Historique:
received: 17 10 2019
revised: 29 05 2020
accepted: 06 06 2020
pubmed: 21 6 2020
medline: 15 12 2020
entrez: 21 6 2020
Statut: ppublish

Résumé

Although there is no unanimity, growing evidence supports the value of regular physical exercise to prevent Alzheimer's disease as well as cognitive decline in affected patients. Together with an introductory summary on epidemiological evidence, the aim of this review is to summarize the current knowledge on the potential biological mechanisms underlying exercise benefits in this condition. Regular physical exercise has proven to be beneficial for traditional cardiovascular risk factors (e.g., reduced vascular flow, diabetes) involved in the pathogenesis of Alzheimer's disease. Exercise also promotes neurogenesis via increases in exercise-induced metabolic factors (e.g., ketone bodies, lactate) and muscle-derived myokines (cathepsin-B, irisin), which in turn stimulate the production of neurotrophins such as brain-derived neurotrophic factor. Finally, regular exercise exerts anti-inflammatory effects and improves the brain redox status, thereby ameliorating the pathophysiological hallmarks of Alzheimer's disease (e.g., amyloid-β deposition). In summary, physical exercise might provide numerous benefits through different pathways that might, in turn, help prevent risk and progression of Alzheimer's disease. More evidence is needed, however, based on human studies.

Identifiants

pubmed: 32561386
pii: S1568-1637(20)30243-9
doi: 10.1016/j.arr.2020.101108
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101108

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Pedro L Valenzuela (PL)

Systems Biology Department, University of Alcalá, Madrid, Spain.

Adrián Castillo-García (A)

Fissac - Physiology, Health, and Physical Activity, Madrid, Spain.

Javier S Morales (JS)

Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.

Pedro de la Villa (P)

Systems Biology Department, University of Alcalá, Madrid, Spain; Institute Ramón y Cajal for Health Research (IRYCIS), Madrid, Spain.

Harald Hampel (H)

Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Enzo Emanuele (E)

2E Science, Robbio, Pavia, Italy.

Simone Lista (S)

Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l'hôpital, F-75013, Paris, France; Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Boulevard de l'hôpital, F-75013, Paris, France.

Alejandro Lucia (A)

Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain; Research Institute Hospital 12 de Octubre (i+12) and Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable, Madrid, Spain. Electronic address: alejandro.lucia@universidadeuropea.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH